<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00477451</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-002-201</org_study_id>
    <nct_id>NCT00477451</nct_id>
  </id_info>
  <brief_title>Staccato Alprazolam in Panic Attack</brief_title>
  <official_title>Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are developing Staccato™ Alprazolam for the treatment of Panic attacks associated with
      panic disorder. This study will provide an initial assessment of efficacy, and to continue to
      describe the tolerability and pharmacokinetics, of a single inhaled dose of Staccato
      Alprazolam on a doxapram-induced panic attack in patients with panic disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted at multiple centers. A total of 42 male and female panic disorder
      patients will be studied. The first 6 subjects will receive Staccato Alprazolam 1 mg open
      label to validate the dose selection. The remaining 36 subjects will be treated with either
      Staccato Alprazolam at the chosen dose; or with Staccato Placebo in a double blind,
      randomized order.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Doxapram-induced Panic Attack</measure>
    <time_frame>0 to 2 hours</time_frame>
    <description>doxapram-induced panic attack of sufficient intensity (DIPASI) defined as a 10 or greater increase from baseline in the acute panic inventory (API)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of the Doxapram-induced Panic Attack</measure>
    <time_frame>1 hr post-dose</time_frame>
    <description>Length of time from the doxapram injection to the time at which the acute panic inventory (API) value returns to within 10 points of the baseline API value. 0=never exceeded 0, 61=exceeded by more than 10 points still at end of assessment of 60 minutes. Thus each would have a duration whether or not they had a panic attack (DIPASI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Borg Max Change From Baseline</measure>
    <time_frame>45 minutes</time_frame>
    <description>Subjects asked to &quot;Point to the number (0 to 10) which matches how breathless you feel now&quot; where 0=nothing at all to 10=very, very strong</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Treatment of Induced Panic Attack</condition>
  <arm_group>
    <arm_group_label>RCT Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RCT Alprazolam 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Inhaled Alprazolam 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initial Inhaled Alprazolam 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Inhaled Staccato Alprazolam Placebo</description>
    <arm_group_label>RCT Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled alprazolam 1 mg</intervention_name>
    <description>Inhaled Staccato Alprazolam 1 mg</description>
    <arm_group_label>RCT Alprazolam 1 mg</arm_group_label>
    <arm_group_label>Open Label Inhaled Alprazolam 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled alprazolam 2 mg</intervention_name>
    <description>Inhaled Staccato Alprazolam 2 mg</description>
    <arm_group_label>Initial Inhaled Alprazolam 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV doxapram</intervention_name>
    <description>0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
    <arm_group_label>RCT Placebo</arm_group_label>
    <arm_group_label>RCT Alprazolam 1 mg</arm_group_label>
    <arm_group_label>Open Label Inhaled Alprazolam 1 mg</arm_group_label>
    <arm_group_label>Initial Inhaled Alprazolam 2 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who meet DSM-IV criteria for panic disorder, with or without agoraphobia.

          2. Subjects who have had at least one panic attack per week in each of the four weeks
             prior to the start of treatment and/or have a Mobility Inventory Score of 3.3 (alone)
             or 2.5 (accompanied).

          3. Male or female subjects who are English-speaking between 18 and 55 years of age.

          4. Female subjects who are not pregnant, or are surgically sterile or 2 years
             postmenopausal. If of childbearing potential, she must be using a medically-accepted
             method of birth control and agree to continue use of this method for at least 30 days
             after the study (i.e., barrier method with spermicide, steroidal contraceptive [oral,
             transdermal, and implanted, including Depo-Provera; contraceptives must be used in
             conjunction with a barrier method], or intrauterine device).

          5. Subjects who are medically healthy (i.e. without a clinically significant unstable
             medical condition such as asthma, coronary artery disease, renal insufficiency, etc.)

          6. Subjects who are able to give informed consent for participation.

          7. Subjects who are able to be withdrawn from current panic disorder medication because
             it is ineffective.

        Exclusion Criteria:

          1. Subjects who have met DSM-IV criteria for substance abuse or dependence within six
             months of study entry must be excluded.

          2. Subjects with a baseline Acute Panic Inventory (22 item test) score of 41 or higher on
             the test day must be excluded.

          3. Subjects who are taking benzodiazepines, SSRIs, or medication that is effective for
             the prevention or treatment of the patient's panic disorder (i.e., no patient will be
             withdrawn for medication that is working for the purpose of entry into this study)
             must be excluded.

          4. Subjects who are clinically depressed must be excluded.

          5. Subjects who have received an investigational drug within 30 days (or within 5 half
             lives of the investigational drug) prior to test day must be excluded.

          6. Subjects with epilepsy or other convulsive disorders must be excluded.

          7. Subjects with a history of allergy or intolerance to benzodiazepines or related drugs
             (alprazolam, lorazepam, diazepam, etizolam, clonazepam, adinazolam) must be excluded.

          8. Subjects who test positive for alcohol or have a positive urine drug screen for
             illicit or disallowed drugs must be excluded. Subjects should refrain from consuming
             alcohol for at least 48 hours prior to dosing.

          9. Female subjects who are breastfeeding or have a positive pregnancy test must be
             excluded.

         10. Subjects who have any other disease or condition, by history, physical examination, or
             laboratory abnormalities that in the investigator's opinion, would present undue risk
             to the subject, or may confound the interpretation of study results must be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanjay Mathew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremy Coplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York - Downstate Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Papp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203-2056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai School Of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2007</study_first_submitted>
  <study_first_submitted_qc>May 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2007</study_first_posted>
  <results_first_submitted>March 12, 2017</results_first_submitted>
  <results_first_submitted_qc>June 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2017</results_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staccato™ Alprazolam, Panic Attack, Inhaled alprazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
    <mesh_term>Doxapram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>RCT Placebo</title>
          <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="P2">
          <title>RCT Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="P3">
          <title>Open Label Inhaled Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="P4">
          <title>Initial Inhaled Alprazolam 2 mg</title>
          <description>Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
Inhaled alprazolam 2 mg: Inhaled Staccato Alprazolam 2 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>RCT Placebo</title>
          <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="B2">
          <title>RCT Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="B3">
          <title>Open Label Inhaled Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="B4">
          <title>Initial Inhaled Alprazolam 2 mg</title>
          <description>Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
Inhaled alprazolam 2 mg: Inhaled Staccato Alprazolam 2 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="10.2"/>
                    <measurement group_id="B2" value="32.1" spread="9.45"/>
                    <measurement group_id="B3" value="43.1" spread="13.6"/>
                    <measurement group_id="B4" value="37.5" spread="0.707"/>
                    <measurement group_id="B5" value="34.3" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Doxapram-induced Panic Attack</title>
        <description>doxapram-induced panic attack of sufficient intensity (DIPASI) defined as a 10 or greater increase from baseline in the acute panic inventory (API)</description>
        <time_frame>0 to 2 hours</time_frame>
        <population>RCT Population (N=40)</population>
        <group_list>
          <group group_id="O1">
            <title>RCT Placebo</title>
            <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
          <group group_id="O2">
            <title>RCT Alprazolam 1 mg</title>
            <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Doxapram-induced Panic Attack</title>
          <description>doxapram-induced panic attack of sufficient intensity (DIPASI) defined as a 10 or greater increase from baseline in the acute panic inventory (API)</description>
          <population>RCT Population (N=40)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of the Doxapram-induced Panic Attack</title>
        <description>Length of time from the doxapram injection to the time at which the acute panic inventory (API) value returns to within 10 points of the baseline API value. 0=never exceeded 0, 61=exceeded by more than 10 points still at end of assessment of 60 minutes. Thus each would have a duration whether or not they had a panic attack (DIPASI)</description>
        <time_frame>1 hr post-dose</time_frame>
        <population>RCT Population (N=40)</population>
        <group_list>
          <group group_id="O1">
            <title>RCT Placebo</title>
            <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
          <group group_id="O2">
            <title>RCT Alprazolam 1 mg</title>
            <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of the Doxapram-induced Panic Attack</title>
          <description>Length of time from the doxapram injection to the time at which the acute panic inventory (API) value returns to within 10 points of the baseline API value. 0=never exceeded 0, 61=exceeded by more than 10 points still at end of assessment of 60 minutes. Thus each would have a duration whether or not they had a panic attack (DIPASI)</description>
          <population>RCT Population (N=40)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="17.2"/>
                    <measurement group_id="O2" value="9.25" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.368</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Borg Max Change From Baseline</title>
        <description>Subjects asked to &quot;Point to the number (0 to 10) which matches how breathless you feel now&quot; where 0=nothing at all to 10=very, very strong</description>
        <time_frame>45 minutes</time_frame>
        <population>RCT Population (N=40)</population>
        <group_list>
          <group group_id="O1">
            <title>RCT Placebo</title>
            <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
          <group group_id="O2">
            <title>RCT Alprazolam 1 mg</title>
            <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Borg Max Change From Baseline</title>
          <description>Subjects asked to &quot;Point to the number (0 to 10) which matches how breathless you feel now&quot; where 0=nothing at all to 10=very, very strong</description>
          <population>RCT Population (N=40)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" spread="2.85"/>
                    <measurement group_id="O2" value="4.63" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment</time_frame>
      <desc>Adverse events (AEs) were assessed predose and at 13 pre-specified time points as well as whenever spontaneously reported by the subjects or study staff</desc>
      <group_list>
        <group group_id="E1">
          <title>RCT Placebo</title>
          <description>Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled placebo: Inhaled Staccato Alprazolam Placebo
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="E2">
          <title>RCT Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="E3">
          <title>Open Label Inhaled Alprazolam 1 mg</title>
          <description>Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
Inhaled alprazolam 1 mg: Inhaled Staccato Alprazolam 1 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
        <group group_id="E4">
          <title>Initial Inhaled Alprazolam 2 mg</title>
          <description>Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
Inhaled alprazolam 2 mg: Inhaled Staccato Alprazolam 2 mg
IV doxapram: 0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

